Detection of metastases in lymph nodes using quantitative ultrasound

使用定量超声检测淋巴结转移

• 批准号: 8987137
• 负责人: Ernest Joseph Feleppa
• 金额: $ 64.45万
• 依托单位: RIVERSIDE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8987137
• 关键词: Address; Adverse effects; Algorithms; Breast; Cancer Patient; Classification; Clinical; Collaborations; Colorectal; Custom; Data; Databases; Detection; Development; Devices; Diagnosis; Disease; Effectiveness; Evaluation; Foundations; Frequencies; Hawaii; Head and Neck Cancer; Health; Histopathology; Image; In Situ; Laboratories; Laboratory Research; Localized Disease; Lung; Malignant Neoplasms; Medical; Medical center; Metastatic Neoplasm to Lymph Nodes; Methods; Neoplasm Metastasis; New York; Nodal; Operating Rooms; Operative Surgical Procedures; Pathologist; Pathology; Patients; Performance; Prostate; ROC Curve; Recruitment Activity; Research; Risk; Savings; Signal Transduction; Specimen; Staging; Stomach; Surgeon; Systemic disease; Testing; Time; Tissues; Translating; Translations; Treatment Cost; Ultrasonics; Ultrasonography; Universities; Validation; Workload; attenuation; base; cancer therapy; cancer type; clinically significant; cost; design; effective therapy; improved; instrument; instrumentation; lymph nodes; next generation; patient population; prototype; quantitative ultrasound; skills; treatment duration; user-friendly

 DESCRIPTION (provided by applicant): This application proposes an Academic-Industrial Partnership (AIP) consisting of Riverside Research (RR) in New York, NY, as the primary partner in collaboration with the GE Global Research Center (GE) in Niskayuna, NY, as the industrial partner, and with the Stony Brook Medical (SBM) affiliated with the State University of New York in Stony Brook, NY, and the Kuakini Medical Center (KMC) affiliated with the University of Hawaii in Honolulu, HI, as the clinical/academic partners. The proposed project addresses the need for reliable, highly sensitive means of detecting metastases to lymph nodes (LNs) in order to correctly stage and optimally treat cancer. Accordingly, we seek to validate existing encouraging results obtained by RR and KMC using quantitative-ultrasound (QUS) methods for detecting metastases in LNs by applying and evaluating these promising methods using a far larger number of LNs and including a far broader range of cancer types from a more-diverse patient population than has been possible in studies to date. Validation efforts will include development, deployment and evaluation of a pre-prototype ultrasonic instrument for QUS-based detection and imaging of metastases in the pathology laboratory. Successful validation will establish a foundation for translation of the QUS methods into a compact, low-cost instrument for metastases detection in dissected LNs to be used in the pathology laboratory or possibly in the operating room. Successful validation also will establish the foundation for a subsequent instrument that can detect and image nodal metastases intra-operatively in the operating room or pre-operatively in the examination room. The AIP partners will synergize capabilities in the following general ways: RR will provide project oversight and coordination and will apply, refine, and test the QUS methods; GE will provide ultrasound (US) instrumentation by designing, fabricating, and characterizing a pre-prototype device; SBM and KMC will provide clinical support by recruiting patients and acquiring US and histological data from dissected LNs.

 描述（由申请人提供）：本申请提出学术-工业合作伙伴关系 (AIP)，由纽约州纽约市的河滨研究中心 (RR) 组成，作为主要合作伙伴，与纽约州尼斯卡尤纳的 GE 全球研究中心 (GE) 合作，作为产业合作伙伴，并与位于纽约州石溪市的纽约州立大学附属石溪医疗中心（SBM）和位于纽约州石溪市的夏威夷大学附属库阿基尼医疗中心（KMC）合作。夏威夷州檀香山作为临床/学术合作伙伴，提出了对检测淋巴结 (LN) 转移的可靠、灵敏方法的需求，以便正确分期和最佳治疗癌症。因此，我们寻求验证现有的令人鼓舞的结果。由 RR 和 KMC 使用定量超声 (QUS) 方法获得，用于检测 LN 转移，通过使用更多数量的 LN 并包括更广泛的癌症类型来应用和评估这些有前景的方法验证工作将包括开发、部署和评估预原型超声仪器，用于在病理实验室进行基于 QUS 的转移检测和成像。为将 QUS 方法转化为紧凑、低成本的仪器奠定了基础，用于在病理实验室或可能在手术室中使用的解剖淋巴结转移检测，成功的验证也将为后续仪器奠定基础。可以在手术室中或术前在检查室检测和成像淋巴结转移 AIP 合作伙伴将通过以下一般方式协同能力： RR 将提供项目监督和协调，并将应用、完善和测试。 QUS 方法；GE 将通过设计、制造和表征预原型设备来提供超声（US）仪器，而 KMC 将通过招募患者并从解剖中获取超声和组织学数据来提供临床支持； LN。